Compare CRNT & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNT | DERM |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.5M | 213.6M |
| IPO Year | 2000 | 2021 |
| Metric | CRNT | DERM |
|---|---|---|
| Price | $2.11 | $8.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $5.50 | ★ $12.67 |
| AVG Volume (30 Days) | ★ 693.9K | 205.3K |
| Earning Date | 11-11-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $363,330,000.00 | $59,399,000.00 |
| Revenue This Year | N/A | $18.34 |
| Revenue Next Year | $5.06 | $54.69 |
| P/E Ratio | $131.07 | ★ N/A |
| Revenue Growth | N/A | ★ 2.82 |
| 52 Week Low | $1.82 | $3.54 |
| 52 Week High | $5.73 | $9.40 |
| Indicator | CRNT | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 50.28 | 53.72 |
| Support Level | $1.93 | $7.27 |
| Resistance Level | $2.05 | $8.16 |
| Average True Range (ATR) | 0.08 | 0.42 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 98.18 | 68.25 |
Ceragon Networks Ltd is a wireless transport company in terms of unit shipments and wide distribution of its business, providing high-capacity wireless connectivity solutions to markets across various industries, mainly wireless (mobile) networks service providers. Geographically the company generates the key revenue from India. The company also has presence in North America, Europe, Africa, Asia-Pacific and Middle East, and Latin America. The company's products include IP-50 Platform, IP-20 Platform, Pointlink.
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.